The Ljungström family office co-led AnaCardio's €62.5 million Series B alongside Novo Holdings and, two days earlier, came in as a new investor in Breye Therapeutics' €67.5 million Series A. Two commitments of that size inside one week, in a therapeutic area as capital-hungry as clinical-stage biotech, is the kind of activity that usually belongs... Continue reading →